We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: DocGo Inc. is a provider of last-mile telehealth and integrated medical mobility services. DocGo Inc., formerly known as Motion Acquisition Corp., is based in NEW YORK.
- Recent DCGO Stock Price: $3.35
- Yearly Gain for DCGO stock: -59.30%
- Market Cap for DCGO stock: $348.97M
- P/E Ratio for DCGO stock: 55.83
Will DCGO's stock price go up? Is there an accurate DCGO stock forecast available?
TipRanks.com reports that DocGo Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $10.40. The target pricing ranges from a high DCGO forecast of $8 down to a low forecast of $10. DocGo Inc. (DCGO)’s last closing stock price was $3.35 which would put the average price target at 210.45% upside.
In addition, TradingView issued a rating for DCGO stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DCGO stock.
Other analysts covering DCGO include:
- David Grossman of Stifel Nicolaus issued a Buy rating with the price target of $8 on 20 hours ago
- David Larsen of BTIG issued a Buy rating with the price target of $11 on 1 day ago
- Michael Latimore of Northland Securities issued a Buy rating with the price target of $12 on 1 month ago
- Sarah James of Cantor Fitzgerald issued a Buy rating with the price target of $11 on 1 month ago
If you are wondering if DCGO is a good stock to buy, here are 3rd party ratings for DCGO stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 19% (47 out of 252)
What is the sentiment on the street regarding DocGo Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for DCGO stock: Bearish
- Blogger Consensus for DCGO stock:
- Media Buzz for DCGO stock: Buy
- Insider Signal for DCGO stock: Selling
- Investor Sentiment for DCGO stock: Negative
- Hedge Fund signal for DCGO stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on DCGO stock including scouring the social networks like DCGO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DCGO stock chart >>
Summary: Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Poseida Therapeutics Inc. is based in San Diego, California.
- Recent PSTX Stock Price: $2.79
- Yearly Gain for PSTX stock: 3.72%
- Market Cap for PSTX stock: $269.20M
- P/E Ratio for PSTX stock: -2.04
Will PSTX's stock price go up? Is there an accurate PSTX stock forecast available?
TipRanks.com reports that Poseida Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $14.00. The target pricing ranges from a high PSTX forecast of $20 down to a low forecast of $10. Poseida Therapeutics, Inc. (PSTX)’s last closing stock price was $2.79 which would put the average price target at 401.79% upside.
In addition, TradingView issued a rating for PSTX stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on PSTX stock.
Other analysts covering PSTX include:
- Justin Zelin of BTIG issued a Buy rating with the price target of $12 on 1 day ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $10 on 1 month ago
- Jennifer Kim of Cantor Fitzgerald issued a Buy rating with the price target of $14 on 5 months ago
If you are wondering if PSTX is a good stock to buy, here are 3rd party ratings for PSTX stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Sell, Top 32% (80 out of 252)
What is the sentiment on the street regarding Poseida Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for PSTX stock: Bearish
- Blogger Consensus for PSTX stock:
- Media Buzz for PSTX stock: Neutral
- Insider Signal for PSTX stock: Selling
- Investor Sentiment for PSTX stock: Positive
- Hedge Fund signal for PSTX stock: High Risk
The stock market is extremely volatile, and you need to do your own research on PSTX stock including scouring the social networks like PSTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PSTX stock chart >>
Summary: Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts.
- Recent INZY Stock Price: $5.24
- Yearly Gain for INZY stock: -3.68%
- Market Cap for INZY stock: $323.69M
- P/E Ratio for INZY stock: -3.82
Will INZY's stock price go up? Is there an accurate INZY stock forecast available?
TipRanks.com reports that Inozyme Pharma, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $22.75. The target pricing ranges from a high INZY forecast of $40 down to a low forecast of $14. Inozyme Pharma, Inc. (INZY)’s last closing stock price was $5.24 which would put the average price target at 334.16% upside.
In addition, TradingView issued a rating for INZY stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on INZY stock.
Other analysts covering INZY include:
- Tazeen Ahmad of Bank of America Securities issued a Buy rating with the price target of $14 on 1 day ago
- Edward White of H.C. Wainwright issued a Buy rating with the price target of $14 on 1 day ago
- Christopher Raymond of Piper Sandler issued a Buy rating with the price target of $40 on 9 months ago
If you are wondering if INZY is a good stock to buy, here are 3rd party ratings for INZY stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 32% (80 out of 252)
What is the sentiment on the street regarding Inozyme Pharma, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for INZY stock: Bullish
- Blogger Consensus for INZY stock:
- Media Buzz for INZY stock: Sell
- Insider Signal for INZY stock: Balanced
- Investor Sentiment for INZY stock: Positive
- Hedge Fund signal for INZY stock: High Risk
The stock market is extremely volatile, and you need to do your own research on INZY stock including scouring the social networks like INZY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for INZY stock chart >>
Summary: Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.
- Recent NRIX Stock Price: $15.69
- Yearly Gain for NRIX stock: 75.70%
- Market Cap for NRIX stock: $767.15M
- P/E Ratio for NRIX stock: -5.92
Will NRIX's stock price go up? Is there an accurate NRIX stock forecast available?
TipRanks.com reports that Nurix Therapeutics, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $25.00. The target pricing ranges from a high NRIX forecast of $31 down to a low forecast of $20. Nurix Therapeutics, Inc. (NRIX)’s last closing stock price was $15.69 which would put the average price target at 59.34% upside.
In addition, TradingView issued a rating for NRIX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NRIX stock.
Other analysts covering NRIX include:
- Derek Archila of Wells Fargo issued a Buy rating with the price target of $20 on 1 day ago
- Eric Joseph of J.P. Morgan issued a Buy rating with the price target of $30 on 1 day ago
- Peter Lawson of Barclays issued a Buy rating with the price target of $20 on 1 week ago
- Joel Beatty of Robert W. Baird issued a Buy rating with the price target of $24 on 1 week ago
If you are wondering if NRIX is a good stock to buy, here are 3rd party ratings for NRIX stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 32% (80 out of 252)
What is the sentiment on the street regarding Nurix Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for NRIX stock: Bearish
- Blogger Consensus for NRIX stock:
- Media Buzz for NRIX stock: Sell
- Insider Signal for NRIX stock: Balanced
- Investor Sentiment for NRIX stock: Positive
- Hedge Fund signal for NRIX stock: High Risk
The stock market is extremely volatile, and you need to do your own research on NRIX stock including scouring the social networks like NRIX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NRIX stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================